You are on page 1of 1

Erceflora- MIMS Class Antidiarrheals

Indications: Acute diarrhea with duration of 14 days due to infection, drugs or poisons. Chronic or persistent diarrhea with duration of >14 days Administration at regular intervals (3-4 hrs), diluting the content of the vial in sweetened water, milk, tea or orange juice.Shake the vial before use. Overdosage Up to the present time, no clinical manifestations of overdose have been reported. Special Precautions During antibiotic therapy, Erceflora should be administered in the interval between 1 dose of antibiotic and the next. Side Effects No side effects have been reported, up to the present time, with the use of the drug. Drug Interactions There are no known interactions subsequent to the concomitant use of other drugs. Caution For Usage The possible presence of corpuscles visible in the vials of Erceflora is due to aggregates of Bacillus clausii spores and does not, therefore indicate that Erceflora has undergone changes. Description Erceflora also contains sterile distilled water. Mechanism of Action Erceflora is a preparation consisting of suspension of Bacillus clausii spores, normal inhabitants of the intestine, with no pathogenic powers. Administered orally, Bacillus clausii spores, due to their high-resistance to both chemical and physical agents, cross the barrier of the gastric juices reaching unharmed the intestinal tract where they are transformed into metabolically active vegetative cells. The administration of Bacillus clausii contributes to the recovery of the intestinal microbial flora altered during the course of microbial disorders of diverse origin. Bacillus clausii is capable of producing various vitamins, in particular group B vitamins, hence it contributes to correcting the consequent vitamin disorders caused by antibiotics and chemotherapeutic agents in general. Bacillus clausii makes it possible to obtain a non-specific antigenic & antitoxic action, closely connected with the metabolic action of clausii. In addition, the high degree of heterologous resistance to the antibiotics induced artificially, provides for the creation of the therapeutic basis for preventing the alteration of the intestinal microbial flora, following the selective action of antibiotics, especially the broad-spectrum ones or to re-establish its balance. Due to its antibiotic resistance, Bacillus clausii can be administered in the interval between 2 doses of antibiotic. The antibiotic-resistance refers to penicillin, cephalosporins, tetracyclines, macrolides, aminoglycosides, novobiocin, chloramphenicol, thiamphenicol, lincomycin, isoniazid, cycloserine, rifampicin, nalidixic acid and pipemidic acid.

Patient Education for PCOP


Counsel parents regarding the need to prevent exposure of infants to tobacco smoke, and, as part of anticipatory primary care, educate parents regarding later infectious exposures in daycare centers, schools, and similar settings as well as the importance of hand washing. In addition, discuss the benefit infants may receive from pneumococcal immunization and annual influenza immunization and the potential benefits and costs of RSV immune globulin (see Prevention). Emphasize careful longitudinal surveillance for long-term problems with growth, development, otitis, reactive airway disease, and other complications. Most children treated with outpatient antibiotics are much improved within 48 hours after the initiation of treatment. Educate parents about and caution them to look for the signs of increasing respiratory distress and to seek medical attention immediately should any of these signs appear.